ICYMI: We welcomed Chris Boulton as CEO and announced a $70M Series A to advance ultra-long-acting therapies for obesity and metabolic disease. We’re encouraged by the engagement around our extended-duration approaches and look forward to sharing continued progress. #medsky https://bit.ly/4a6LdhP

Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by 5AM Ventures, OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/4a6LdhP #biosky